Clearstead Trust LLC Cuts Position in Illumina, Inc. (NASDAQ:ILMN)

Clearstead Trust LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 31.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 195 shares of the life sciences company’s stock after selling 88 shares during the quarter. Clearstead Trust LLC’s holdings in Illumina were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in ILMN. Cambridge Investment Research Advisors Inc. grew its stake in Illumina by 43.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 7,398 shares of the life sciences company’s stock worth $1,016,000 after buying an additional 2,258 shares during the last quarter. Stratos Wealth Partners LTD. grew its position in Illumina by 8.4% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 5,275 shares of the life sciences company’s stock worth $724,000 after purchasing an additional 410 shares during the last quarter. Independent Advisor Alliance raised its holdings in shares of Illumina by 8.6% in the third quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company’s stock worth $219,000 after buying an additional 126 shares during the last quarter. Brown Advisory Inc. lifted its stake in shares of Illumina by 4.4% during the third quarter. Brown Advisory Inc. now owns 4,140 shares of the life sciences company’s stock worth $568,000 after buying an additional 176 shares during the period. Finally, Hixon Zuercher LLC increased its position in shares of Illumina by 53.6% in the 3rd quarter. Hixon Zuercher LLC now owns 11,943 shares of the life sciences company’s stock valued at $1,640,000 after acquiring an additional 4,168 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Down 4.9 %

Shares of ILMN stock traded down $6.06 on Friday, hitting $117.93. 2,987,105 shares of the stock traded hands, compared to its average volume of 1,375,095. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $213.91. The firm’s 50-day moving average price is $130.03 and its two-hundred day moving average price is $127.00. The stock has a market capitalization of $18.78 billion, a PE ratio of -14.47 and a beta of 1.20.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.28%. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.08 EPS. As a group, analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ILMN shares. Barclays lifted their target price on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. Robert W. Baird raised their price target on shares of Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research report on Friday. Stephens restated an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. Finally, HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $165.10.

Insider Buying and Selling

In related news, CEO Jacob Thaysen acquired 7,330 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.17% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.